Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM)
Clinical trial NCT05509530 · UNKNOWN
Trial details
- NCT number
- NCT05509530
- Sponsor
- Xuzhou Medical University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-01
- Primary completion
- 2025-05-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.